Article Text

PDF
Response to: ‘Time to personalise the treatment of anti-MDA-5 associated lung disease’ by Lake et al
  1. Valérie Leclair1,2,
  2. Ingrid E Lundberg1,
  3. Anna Tjärnlund1
  1. 1Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
  2. 2Rheumatology Unit, Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada
  1. Correspondence to Anna Tjärnlund, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; anna.tjarnlund{at}ki.se

Statistics from Altmetric.com

We have with interest read the comments raised by Lake et al in the e-letter titled ‘Time to personalise the treatment of anti-MDA-5 associated lung disease’ to be published in your journal.1 We thank the authors for sharing their insights on the 2017 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.2 Lake and colleagues are concerned that these classification criteria are not including rare specific subsets such as dermatomyositis (DM) or amyopathic DM associated with antimelanoma differentiation-associated protein 5 (MDA5). They fear that this will in turn prevent clinicians and researchers from exploring new therapeutic approaches for this population frequently affected by rapidly progressive interstitial lung disease (RPILD), a complication associated with fatal outcomes.3 4 Dr Malaviya raised a similar concern when discussing the importance of myositis-specific autoantibodies (MSA) in classifying subgroups of IIM, exemplified by …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles